IP Library Granted Patent US 11,787,922
Granted Patent B2
US 11,787,922 · App. 17/588,542 · Granted Oct 17, 2023

Hydrophobically modified chitosan compositions

Inventor: Matthew Dowling (Riverdale, MD)
Assignee: Medcura, Inc.
C08L5/08A61L15/26A61L15/28A61L24/08C08B37/003C08L71/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,787,922
App. No.
17/588,542
Granted
Oct 17, 2023
Kind
B2
Abstract

Disclosed herein is a polymer composition comprising an effective amount of a hydrophobically-modified polymer having functional groups along the backbone occupied by a fatty anhydride moiety. The polymer composition has a potent hemostatic action by gelling blood upon contact, and is suitable for treating internal and external bleeds. As disclosed herein, the modified polymer can be generated without the use of toxic reagents that would require removal from the product. Further, compositions are shelf stable even in a flowable form. That is, the hydrophobic grafts are not lost under product storage conditions (e.g., room temperature storage).

Claims (23)

1. A method for treating a wound in a patient, comprising, applying a polymer composition comprising an effective amount of a hydrophobically-modified chitosan having hydrocarbon groups attached to the chitosan backbone through amide linkages to a wound, wherein the composition is formulated with a pH of about 5 or less, wherein the hydrocarbon groups comprise C8 to C18 hydrocarbon groups in an effective amount to form an artificial clot in the presence of blood.

2. The method of claim 1 , wherein the polymer composition is a gel.

3. The method of claim 1 , wherein the polymer composition is a lyophilized sponge.

4. The method of claim 1 , wherein the polymer composition is a film.

5. The method of claim 1 , wherein the polymer composition is a powder.

6. The method of claim 1 , wherein the polymer composition is a foam.

7. The method of claim 1 , wherein the polymer composition is a putty.

8. The method of claim 1 , wherein the hydrophobically-modified chitosan has about 1% to about 10% of available amines substituted with a hydrocarbon group.

9. The method of claim 8 , wherein the hydrophobically-modified chitosan has less than about 3% of available amines substituted with a hydrocarbon group.

10. The method of claim 9 , wherein at least one hydrocarbon group is a linear C14, C16, or C18 hydrocarbon moiety.

11. The method of claim 10 , wherein the chitosan has an average molecular weight of from about 40,000 to about 500,000 Daltons.

12. The method of claim 8 , wherein the hydrophobically-modified chitosan has 2 or 3 different hydrocarbon groups conjugated along the chitosan backbone.

13. The method of claim 12 , having a population of C6 to C12 hydrocarbon groups, and a population of C14 to C18 hydrocarbon groups.

14. The method of claim 13 , wherein the hydrophobic groups further comprise C1 to C4 hydrocarbon groups.

15. The method of claim 1 , wherein the composition is formulated in a dilute organic acid, the organic acid having a pKa of from about 2 to about 5.

16. The method of claim 15 , wherein the organic acid is lactic acid, acetic acid, formic acid, or malic acid.

17. The method of claim 15 , wherein the hydrophobically-modified chitosan is present at 0.1 to about 5% by weight.

18. The method of claim 15 , wherein the organic acid is present in the composition from about 0.05M to 0.4M.

19. The method of claim 1 , wherein the composition further comprises at least one synthetic polymer.

20. The method of claim 19 , wherein the synthetic polymer is a polythene, polystyrene, polyacrylate, polyamide, polyester, polyurethane, polysulfide, or polycarbonate.

21. The method of claim 19 , wherein the synthetic polymer is a polyethylene glycol.

22. The method of claim 1 , wherein the wound has high exudate or blood flow.

23. The method of claim 1 , wherein the wound is selected from a pressure sore, diabetic ulcer, leg ulcer, donor site, graft site, surgical wound, skin abrasion or laceration, 1 st or 2 nd degree burn, and trauma wound.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2023
From: DOWLING, MATTHEW
To: GEL-E, INC.
Reel/Frame 064863/0114 →
CHANGE OF NAME Recorded Sep 11, 2023
From: GEL-E, INC.
To: MEDCURA, INC.
Reel/Frame 064867/0767 →
Continuity (4)
Continuation 16592234 · Oct 3, 2019
Continuation In Part PCTUS2018027637 · Apr 13, 2018
Provisional Application 62484985 · Apr 13, 2017
Related Publication 20220227974A1 · Jul 21, 2022
Cited By (3)
US 12,201,742 US 12,403,157 US 12,643,993